Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 16;3(4):794–803. doi: 10.1016/j.ekir.2018.03.006

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Rankings of surface under the cumulative ranking area (SUCRA) for efficacy of treatments to induce end points in IgA nephropathy. (a) Clinical remission, (b) end-stage renal disease (ESRD) and doubling of serum creatinine level, and (c) serious adverse events (SAEs) of IgAN. The graphs display the distribution of probabilities of treatment, ranking from the best through the worst for each outcome. Ranking indicates the probability that the drug class is “best,” second-“best,” etc. For example, RAS inhibitors plus urokinase and steroid combined with tonsillectomy were among the best treatments for inducing disease remission, while the placebo provided the lowest probability of disease remission (worst). On the other hand, the ranking suggests that MMF posed the highest risk for incurring ESRD or creatinine doubling (worst), whereas renin−angiotensin system (RAS) inhibitors (RASi) plus steroid incurred the lowest probability of ESRD or creatinine doubling (best). MMF, mycophenolate mofetil; TSP, tonsillectomy combined with steroid pulse therapy.

Rankings of surface under the cumulative ranking area (SUCRA) for efficacy of treatments to induce end points in IgA nephropathy. (a) Clinical remission, (b) end-stage renal disease (ESRD) and doubling of serum creatinine level, and (c) serious adverse events (SAEs) of IgAN. The graphs display the distribution of probabilities of treatment, ranking from the best through the worst for each outcome. Ranking indicates the probability that the drug class is “best,” second-“best,” etc. For example, RAS inhibitors plus urokinase and steroid combined with tonsillectomy were among the best treatments for inducing disease remission, while the placebo provided the lowest probability of disease remission (worst). On the other hand, the ranking suggests that MMF posed the highest risk for incurring ESRD or creatinine doubling (worst), whereas renin−angiotensin system (RAS) inhibitors (RASi) plus steroid incurred the lowest probability of ESRD or creatinine doubling (best). MMF, mycophenolate mofetil; TSP, tonsillectomy combined with steroid pulse therapy.